TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ENVISIA

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

ENVISIA

ST13

US500000097815166

Classe

1, 5

Pedido

97815166

Registro

8098213

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

25

Atualização mais recente

13/01/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5

Data de depósito

28/02/2023

Data de registro

13/01/2026

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

13/01/2026

Última transação

13/01/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Primeiro uso

17/05/2018

Primeiro uso no comércio

17/05/2018

Código do desenho

4

Tipo de titular

03

Localização do titular

South San Francisco, CA, US

Examinador

LEVINE,HOWARD B

Unidade examinadora

M60

Localização atual

FILE REPOSITORY (FRANCONIA)

Titulares e representantes

Titulares

Veracyte, Inc.

Representantes

Rosaleen H. Chou KNOBBE, MARTENS, OLSON & BEAR, LLP

Classificação técnica

Classes Nice

Classe 1Classe 5

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

Reagents for scientific or research use; Diagnostic kits and test kits primarily composed of reagents for determination of genomic and transcriptomic information for scientific or research purposes; Testing kits comprised primarily of preparations, reagents, test strips, collection tubes, buffers, tube holders, transport bags and assays for use in scientific or research in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Biological agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for scientific and research use; Diagnostic reagents and preparations, other than for medical and veterinary use; Kits comprised primarily of biological reagents and comprised secondarily of a protocol in the form of printed instructions for use thereof for scientific and research purposes; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for scientific or research purposes; Reagents and molecule or cell markers for scientific or research purposes

Classe 5

Kits for in vitro diagnostic testing for pulmonary diseases and conditions; Reagents for medical use; Molecular diagnostic assays for testing of bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Medical preparations used to diagnose bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Diagnostic agents, preparations and substances for medical purposes; Diagnostic test kits consisting primarily of reagents for use in testing bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Medical diagnostic test kits consisting primarily of reagents for detecting pathogens; Clinical medical diagnostic reagents, medical diagnostic assays for medical and diagnostic purposes for testing genetic material; Clinical, genetic and specialized medical diagnostic test kits comprised primarily of buffers, collection tubes, tube holders, transport bags, shipping containers, and instruction sheets for use in scientific and clinical diagnostic equipment used to detect disease, cancer, genetics, and pathogens; Chemicals, assays, reagents and kits consisting primarily of chemicals, assays, and reagents for medical testing and diagnostic purposes in the fields of genomics, diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Medical diagnostic reagents, and kits comprised of medical diagnostic reagents, collection tubes, buffers, tube holders, transport bags, and instruction sheets, for diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Medical diagnostic testing kits comprised primarily of reagents and assays for use in diagnostics and diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for medical diagnostic use

Publicações

Histórico de despachos e eventos da marca no USPTO.

25 publicações encontradas

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

13/01/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

13/01/2026

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

25/11/2025

PUBO

PUBLISHED FOR OPPOSITION

25/11/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

19/11/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

28/10/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

27/10/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

27/10/2025

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

27/10/2025

RCSC

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED

25/06/2025

RCSC

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED

27/12/2024

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

28/06/2024

GNSL

LETTER OF SUSPENSION E-MAILED

28/06/2024

CNSL

SUSPENSION LETTER WRITTEN

28/06/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

29/05/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

29/05/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

29/05/2024

XELG

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

22/02/2024

XELR

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

22/02/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

29/11/2023

GNRT

NON-FINAL ACTION E-MAILED

29/11/2023

CNRT

NON-FINAL ACTION WRITTEN

29/11/2023

DOCK

ASSIGNED TO EXAMINER

29/11/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

19/03/2023

NWAP

NEW APPLICATION ENTERED

03/03/2023

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ENVISIA ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.